|
1.
|
Foundation for Promotion of Cancer
Research (FPCR): Number of deaths by cancer site (2011). http://ganjoho.jp/data/public/statistics/backnumber/2012/files/fig01.pdf.
Accessed April 10, 2013.
|
|
2.
|
Ishii H, Furuse J, Boku N, et al: Phase II
study of gemcitabine chemotherapy alone for locally advanced
pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Nagakawa T, Kurachi M, Konishi K and
Miyazaki I: Translateral retroperitoneal approach in radical
surgery for pancreatic carcinoma. Jpn J Surg. 12:229–233. 1982.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Nagakawa T, Nagamori M, Futakami F, et al:
Results of extensive surgery for pancreatic carcinoma. Cancer.
77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Miwa K, Ohta T, Shimizu K, et al:
Augmented regional pancreaticoduodenectomy for pancreas head
cancer: combined resection of pancreas head and superior mesenteric
artery and vein. In: American College of Surgeons, 90th Annual
Clinical Congress; New Orleans, LA. pp. 1902004
|
|
6.
|
Evans DB, Abbruzzese JL and Willett CG:
Cancer of the pancreas. Cancer: Principles and Practice of
Oncology. DeVita VT Jr, Hellman S and Rosenberg SA: 6th edition.
Lippincott Williams and Wilkins; Philadelphia: pp. 1126–1161.
2001
|
|
7.
|
Oettle H, Post S, Neuhaus P, et al:
Adjuvant chemotherapy with gemcitabine vs observation in patients
undergoing curative-intent resection of pancreatic cancer: a
randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
|
|
8.
|
Klinkenbijl JH, Jeekel J, Sahmoud T, et
al: Adjuvant radiotherapy and 5-fluorouracil after curative
resection of cancer of the pancreas and periampullary region: phase
III trial of the EORTC Gastrointestinal Tract Cancer Cooperative
Group. Ann Surg. 230:776–782. 1999. View Article : Google Scholar
|
|
9.
|
Spitz FR, Abbruzzese JL, Lee JE, et al:
Preoperative and postoperative chemoradiation strategies in
patients treated with pancreaticoduodenectomy for adenocarcinoma of
the pancreas. J Clin Oncol. 15:928–937. 1997.PubMed/NCBI
|
|
10.
|
Yeo CJ, Abrams RA, Grochow LB, et al:
Pancreaticoduodenectomy for pancreatic adenocarcinoma:
postoperative adjuvant chemoradiation improves survival. A
prospective, single-institution experience. Ann Surg. 225:621–633.
1997. View Article : Google Scholar
|
|
11.
|
Burris HA, Moore MJ, Andersen J, et al:
Improvements in survival and clinical benefit with gemcitabine as
first-line therapy for patients with advanced pancreatic cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
12.
|
Shirasaka T, Shimamoto Y, Ohshimo H,
Yamaguchi M, et al: Development of a novel form of an oral
5-fluorouracil derivative (S-1) directed to the potentiation of the
tumor selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar
|
|
13.
|
Tatsumi K, Fukushima M, Shirasaki T and
Fujii S: Inhibitory effects of pyrimidine, barbituric acid and
pyrimidine derivatives on 5-fluorouracil degradation in rat liver
extracts. Jpn J Cancer Res. 78:748–755. 1987.PubMed/NCBI
|
|
14.
|
Takechi T, Fujioka A, Matssushima E,
Fukushima M, et al: Enhancement of the antitumor activity of
5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase
activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human
tumor cells. Eur J Cancer. 38:1271–1277. 2002. View Article : Google Scholar
|
|
15.
|
Peters GJ, van Groeningen CJ, Laurensse EJ
and Pinedo HM: A compression of 5-fluorouracil metabolism in human
colorectal cancer and colon mucosa. Cancer. 68:1903–1909. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Takechi T, Nakano K, Uchida J, Mita A, et
al: Antitumor activity and low intestinal toxicity of S-1, a new
formulation of oral tegafur, in experimental tumor models in rats.
Cancer Chemother Pharmacol. 39:205–211. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Nakamura K, Yamaguchi T, Ishihara T, et
al: Phase I trial of oral S-1 combined with gemcitabine in
metastatic pancreatic cancer. Br J Cancer. 92:2134–2139. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ueno H, Okusaka T, Ikeda M, et al: A Phase
I study of combination chemotherapy with gemcitabine and oral S-1
for advanced pancreatic cancer. Oncology. 69:421–427. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Nakamura K, Yamaguchi T, Ishihara T, et
al: Phase II trial of oral S-1 combined with gemcitabine in
metastatic pancreatic cancer. Br J Cancer. 1–5. 2006.PubMed/NCBI
|
|
20.
|
Ioka K, Ikeda M, Ohkawa S, et al:
Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1
versus gemcitabine (GEM) in unresectable advanced pancreatic cancer
(PC) in Japan and Taiwan: GEST study. J Clin Oncol.
29:40072011.
|
|
21.
|
Vento P, Mustonen H, Joensuu T, et al:
Impact of preoperative chemoradiotherapy on survival in patients
with resectable pancreatic cancer. World J Gastroenterol.
21:2945–2951. 2007.PubMed/NCBI
|
|
22.
|
Palmer DH, Stocken DD, Hewitt H, et al: A
Randomized phase 2 trial of neoadjuvant chemotherapy in resectable
pancreatic cancer: gemcitabine alone versus gemcitabine combined
with cisplatin. Ann Surg Oncol. 14:2088–2096. 2007. View Article : Google Scholar
|
|
23.
|
Sato N, Kurashima K, Nagai H, et al: The
effect of adjuvant and neoadjuvant chemo (radio) therapy on
survival in 1,679 resected pancreatic carcinoma cases in Japan:
report of the national survey in the 34th annual meeting of
Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat
Surg. 16:485–492. 2009. View Article : Google Scholar
|
|
24.
|
Tajima H, Ohta T, Kitagawa H, et al: Pilot
study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for
resectable pancreatic cancer. Exp Therap Med. 3:787–792.
2012.PubMed/NCBI
|
|
25.
|
Rauchwerger DR, Firby PS, Hedley DW and
Moore MJ: Equilibrative-sensitive nucleoside transporter and its
role in gemcitabine sensitivity. Cancer Res. 60:6075–6079.
2000.PubMed/NCBI
|
|
26.
|
Makino I, Kitagawa H, Ohta T, et al: Nerve
plexus invasion in pancreatic cancer. Spread patterns on
histopathologic and embryological analysis. Pancreas. 37:358–365.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Evans DB, Rich TA, Byrd DR, et al:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Bassi C, Dervenis C, Butturini G, et al:
Postoperative pancreatic fistula: an International Study Group
(ISGPF) definition. Surgery. 138:8–13. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Esposito I, Kleeff J, Bergmann F, et al:
Most pancreatic cancer resections are R1 resections. Ann Surg
Oncol. 15:1651–1660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Nakahira S, Nakamori S, Tsujie M, et al:
Pretratment with S-1, an oral derivative of 5-fluorouracil,
enhances gemcitabine effect in pancreatic cancer xenografts.
Anticancer Res. 28:179–186. 2008.PubMed/NCBI
|
|
31.
|
Heinrich S, Petalozzi B, Lesurtel M, et
al: Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin
plus adjuvant gemcitabine in resectable pancreatic cancer: a
randomized multicenter phase III study (NEOPAC study). BMC Cancer.
11:346–352. 2011. View Article : Google Scholar
|
